ENHERTU, also known by its scientific name fam-trastuzumab deruxtecan-nxki, is a targeted therapy medication used in the treatment of certain types of cancer. It is specifically designed for patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based regimens. ENHERTU is a conjugate drug that combines a HER2-directed antibody with a chemotherapy agent, allowing for the direct delivery of the chemotherapy to the cancer cells while minimizing the impact on healthy cells. This innovative approach enhances the drug's ability to kill cancer cells while reducing side effects associated with traditional chemotherapy. ENHERTU has shown significant efficacy in clinical trials, offering hope to patients with limited treatment options.
When using ENHERTU, it's crucial to take certain precautions to ensure your safety and the effectiveness of the medication. ENHERTU can cause side effects that may impair your ability to drive or operate machinery safely. Common side effects include nausea, fatigue, hair loss, and decreased white blood cell count, which could increase your risk of infection. Rare but serious side effects, such as lung problems (interstitial lung disease) and decreased heart function, have also been reported. Given these potential side effects, it's essential to closely follow your doctor's instructions and to read the medication guide that comes with ENHERTU. Before starting ENHERTU, inform your doctor about all other medications you're taking, as interactions may occur. Always report any unusual symptoms or side effects to your doctor promptly. Adhering to these guidelines will help manage the risks associated with ENHERTU and contribute to its effectiveness in your treatment plan.